RTA 744 for treatment of malignant glioma receives orphan drug status.Published in:Expert Review of Anticancer Therapy, 2006, v. 6, n. 11, p. 1536Publication type:Article
Deal watch: Abbott boosts investment in NRF2 activators for reducing oxidative stress.Published in:Nature Reviews Drug Discovery, 2012, v. 11, n. 2, p. 96, doi. 10.1038/nrd3655By:Crunkhorn, SarahPublication type:Article